Login to Your Account

Psivida skyrockets on 'extraordinary' phase III Medidur uveitis data

By Amanda Pedersen
Senior Staff Writer

Tuesday, December 22, 2015

Shares of Psivida Corp. shot up to a five-year high on above-average trading volume Tuesday after the company reported positive top-line results from its first phase III trial evaluating Medidur to treat chronic noninfectious uveitis affecting the posterior of the eye. 

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription